SARS-CoV-2 encephalitis is a cytokine release syndrome: evidence from cerebrospinal fluid analyses | Evolution of antibody immunity to SARS-CoV-2 | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality | Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study | Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
Reports of “Long-COVID”, are rising: Attributes and predictors of “Long COVID” | Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity | More people are getting COVID-19 twice, suggesting immunity wanes quickly in some | Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 | ApoE isoform-dependent SARS-CoV-2 neurotropism and cellular response
A distinct innate immune signature marks progression from mild to severe COVID-19 | Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 | Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
Veterans Health Administration COVID-19 (VACO) Index for COVID-19 Mortality | V-safe After Vaccination Health Checker | COVID-19 Vaccines and Severe Allergic Reactions | FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine | K reports new variant, termed VUI 202012/01
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK | FDA issues Emergency Use Authorization for first COVID-19 vaccine
Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 | The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020 | Updated CDC guidance on when to quarantine
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 | Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results | Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Throughout the months of December & January, all donations made to Parasites Without Borders will be matched and DOUBLED by PWB with a pledge up to $40,000 with a minimum donation of $10,000 and donated to Peace Corps’ Health and HIV/AIDS Fund, a fund that helps combat global health issues such as poor nutrition, the spread of infectious diseases, and the devastating social and economic impact of HIV/AIDS.
Immunological memory to SARS-CoV-2 assessed for greater than six months after infection | Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 | Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany | FDA Authorizes First COVID-19 Test for Self-Testing at Home
A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.
Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.
English 
Spanish